Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 18Neoplasm Metastasis 3Endometrial Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Melanoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Liposarcoma 1Leiomyosarcoma 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HR+/HER2- Breast Cancer 1HER2 Negative Breast Cancer 1Glioma 1Glioblastoma 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1ER+ HER2- Advanced Breast Cancer 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms, Male 1Breast Diseases 1Brain Neoplasms 1Astrocytoma 1Advanced Breast Cancer 1

Interventions

ribociclib 1Letrozole 1Goserelin 1Chemotherapy, Adjuvant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2 Negative Breast Cancer × ribociclib × 30 days × Clear all
NCT06953882 2026-05-26

SELECT

Yale University

Phase 2 Recruiting
140 enrolled
Breast

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡